Literature DB >> 25428246

Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.

Sue E Crawford1, Nadim Ajami1, Tracy Dewese Parker1, Noritoshi Kitamoto2, Katsuro Natori3, Naokazu Takeda3, Tomoyuki Tanaka4, Baijun Kou1, Robert L Atmar5, Mary K Estes6.   

Abstract

Noroviruses are responsible for most acute nonbacterial epidemic outbreaks of gastroenteritis worldwide. To develop cross-reactive monoclonal antibodies (MAbs) for rapid identification of genogroup I and II (GI and GII) noroviruses (NoVs) in field specimens, mice were immunized with baculovirus-expressed recombinant virus-like particles (VLPs) corresponding to NoVs. Nine MAbs against the capsid protein were identified that detected both GI and GII NoV VLPs. These MAbs were tested in competition enzyme-linked immunosorbent assays (ELISAs) to identify common epitope reactivities to GI and GII VLPs. Patterns of competitive reactivity placed these MAbs into two epitope groups (groups 1 and 2). Epitopes for MAbs NV23 and NS22 (group 1) and MAb F120 (group 2) were mapped to a continuous region in the C-terminal P1 subdomain of the capsid protein. This domain is within regions previously defined to contain cross-reactive epitopes in GI and GII viruses, suggesting that common epitopes are clustered within the P1 domain of the capsid protein. Further characterization in an accompanying paper (B. Kou et al., Clin Vaccine Immunol 22:160-167, 2015, http://dx.doi.org/10.1128/CVI.00519-14) revealed that MAb NV23 (epitope group 1) is able to detect GI and GII viruses in stool. Inclusion of the GI and GII cross-reactive MAb NV23 in antigen detection assays may facilitate the identification of GI and GII human noroviruses in stool samples as causative agents of outbreaks and sporadic cases of gastroenteritis worldwide.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428246      PMCID: PMC4308866          DOI: 10.1128/CVI.00520-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  55 in total

Review 1.  The epidemiologic and clinical importance of norovirus infection.

Authors:  Robert L Atmar; Mary K Estes
Journal:  Gastroenterol Clin North Am       Date:  2006-06       Impact factor: 3.806

2.  Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope.

Authors:  Tomoyuki Shiota; Michio Okame; Sayaka Takanashi; Pattara Khamrin; Makiko Takagi; Kenji Satou; Yuichi Masuoka; Fumihiro Yagyu; Yuko Shimizu; Hideki Kohno; Masashi Mizuguchi; Shoko Okitsu; Hiroshi Ushijima
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

3.  Adsorption and aggregation properties of norovirus GI and GII virus-like particles demonstrate differing responses to solution chemistry.

Authors:  Allegra K da Silva; Owen V Kavanagh; Mary K Estes; Menachem Elimelech
Journal:  Environ Sci Technol       Date:  2010-12-01       Impact factor: 9.028

4.  Sequence and genomic organization of Norwalk virus.

Authors:  X Jiang; M Wang; K Wang; M K Estes
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

5.  Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico.

Authors:  Hoonmo L Koo; Nadim J Ajami; Zhi-Dong Jiang; Frederick H Neill; Robert L Atmar; Charles D Ericsson; Pablo C Okhuysen; David N Taylor; A Louis Bourgeois; Robert Steffen; Herbert L DuPont
Journal:  J Clin Microbiol       Date:  2010-03-19       Impact factor: 5.948

6.  Proposal for a unified norovirus nomenclature and genotyping.

Authors:  Annelies Kroneman; Everardo Vega; Harry Vennema; Jan Vinjé; Peter A White; Grant Hansman; Kim Green; Vito Martella; Kazuhiko Katayama; Marion Koopmans
Journal:  Arch Virol       Date:  2013-04-25       Impact factor: 2.574

7.  Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies.

Authors:  M E Hardy; T N Tanaka; N Kitamoto; L J White; J M Ball; X Jiang; M K Estes
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

8.  Within-host evolution results in antigenically distinct GII.4 noroviruses.

Authors:  Kari Debbink; Lisa C Lindesmith; Martin T Ferris; Jesica Swanstrom; Martina Beltramello; Davide Corti; Antonio Lanzavecchia; Ralph S Baric
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

9.  Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Authors:  Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

10.  Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003.

Authors:  Ben A Lopman; Mark H Reacher; Ian B Vipond; Dawn Hill; Christine Perry; Tracey Halladay; David W Brown; W John Edmunds; Joyshri Sarangi
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  7 in total

1.  Characterization of cross-reactive norovirus-specific monoclonal antibodies.

Authors:  Baijun Kou; Sue E Crawford; Nadim J Ajami; Rita Czakó; Frederick H Neill; Tomoyuki N Tanaka; Noritoshi Kitamoto; Timothy G Palzkill; Mary K Estes; Robert L Atmar
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

2.  Characterization of a Novel Conformational GII.4 Norovirus Epitope: Implications for Norovirus-Host Interactions.

Authors:  Noelia Carmona-Vicente; Susana Vila-Vicent; David Allen; Roberto Gozalbo-Rovira; Miren Iturriza-Gómara; Javier Buesa; Jesús Rodríguez-Díaz
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

3.  Norovirus-specific immunoglobulin A in breast milk for protection against norovirus-associated diarrhea among infants.

Authors:  Hannah Karen Mina Labayo; Monica J Pajuelo; Kentaro Tohma; Lauren A Ford-Siltz; Robert H Gilman; Lilia Cabrera; Holger Mayta; Gerardo J Sanchez; Anniuska Toledo Cornejo; Caryn Bern; Clyde Dapat; Tomonori Nochi; Gabriel I Parra; Hitoshi Oshitani; Mayuko Saito
Journal:  EClinicalMedicine       Date:  2020-10-05

4.  Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses.

Authors:  Lisa C Lindesmith; Martina Beltramello; Jesica Swanstrom; Taylor A Jones; Davide Corti; Antonio Lanzavecchia; Ralph S Baric
Journal:  Open Forum Infect Dis       Date:  2015-07-01       Impact factor: 3.835

5.  Norovirus Escape from Broadly Neutralizing Antibodies Is Limited to Allostery-Like Mechanisms.

Authors:  Abimbola O Kolawole; Hong Q Smith; Sophia A Svoboda; Madeline S Lewis; Michael B Sherman; Gillian C Lynch; B Montgomery Pettitt; Thomas J Smith; Christiane E Wobus
Journal:  mSphere       Date:  2017-10-18       Impact factor: 4.389

Review 6.  GII.4 Human Norovirus: Surveying the Antigenic Landscape.

Authors:  Michael L Mallory; Lisa C Lindesmith; Rachel L Graham; Ralph S Baric
Journal:  Viruses       Date:  2019-02-20       Impact factor: 5.048

7.  Development of a Specific Anti-capsid Antibody- and Magnetic Bead-Based Immunoassay to Detect Human Norovirus Particles in Stool Samples and Spiked Mussels via Flow Cytometry.

Authors:  Ravo M Razafimahefa; Louisa F Ludwig-Begall; Mamadou Amadou Diallo; Benjamin G Dewals; Alain Vanderplasschen; Olivier Nivelles; Caroline Deketelaere; Axel Mauroy; Etienne Thiry
Journal:  Food Environ Virol       Date:  2021-08-07       Impact factor: 2.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.